Robert W. Baird

Marketsmodernreaders.com

Planet Fitness (NYSE:PLNT) Earns “Buy” Rating from Robert W. Baird

Other equities analysts also recently issued research reports about the company. Roth Capital lifted their price objective on Planet Fitness from $62.00 to $75.00 and gave the company a neutral rating in a research report on Friday, February 19th. Macquarie boosted their target price on Planet Fitness from $75.00 to $90.00 and gave the stock an outperform rating in a research report on Friday, February 19th. JPMorgan Chase & Co. boosted their target price on Planet Fitness from $72.00 to $82.00 and gave the stock a neutral rating in a research report on Monday, April 12th. They noted that the move was a valuation call. Cowen restated a market perform rating and set a $85.00 target price on shares of Planet Fitness in a research report on Wednesday, March 10th. Finally, Piper Sandler dropped their target price on Planet Fitness from $87.00 to $82.00 and set a neutral rating for the company in a research report on Friday, May 7th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $80.08.
Picture for Planet Fitness (NYSE:PLNT) Earns “Buy” Rating from Robert W. Baird
Financial Reportsmodernreaders.com

Physicians Realty Trust (NYSE:DOC) Downgraded to Neutral at Robert W. Baird

A number of other brokerages also recently weighed in on DOC. Morgan Stanley raised shares of Physicians Realty Trust from an “equal weight” rating to an “overweight” rating and set a $20.00 price target on the stock in a report on Monday, March 15th. Zacks Investment Research raised shares of Physicians Realty Trust from a “sell” rating to a “hold” rating in a report on Monday, March 1st. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $20.00.
Picture for Physicians Realty Trust (NYSE:DOC) Downgraded to Neutral at Robert W. Baird
RELATED CHANNELS
Businessmodernreaders.com

Robert W. Baird Reiterates “Buy” Rating for Walgreens Boots Alliance (NASDAQ:WBA)

Other analysts have also issued research reports about the company. Barclays raised their price target on Walgreens Boots Alliance from $47.00 to $55.00 and gave the stock an “equal weight” rating in a research note on Monday, April 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Walgreens Boots Alliance in a research report on Wednesday, June 9th. Mizuho lifted their price target on Walgreens Boots Alliance from $47.00 to $55.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 12th. They noted that the move was a valuation call. Truist Financial increased their price objective on shares of Walgreens Boots Alliance from $50.00 to $58.00 in a research report on Thursday, April 1st. Finally, Truist Securities upped their price objective on Walgreens Boots Alliance from $50.00 to $58.00 in a research report on Thursday, April 1st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. Walgreens Boots Alliance presently has a consensus rating of “Hold” and an average target price of $49.53.
Stocksmodernreaders.com

Robert W. Baird Reaffirms “Buy” Rating for IBEX (NASDAQ:IBEX)

Separately, Zacks Investment Research upgraded shares of IBEX from a hold rating to a buy rating and set a $23.00 price target on the stock in a research note on Wednesday, June 9th. Seven investment analysts have rated the stock with a buy rating, IBEX currently has a consensus rating of Buy and a consensus price target of $22.38.
Marketsmodernreaders.com

Biogen (NASDAQ:BIIB) Lifted to Neutral at Robert W. Baird

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a buy rating on shares of Biogen in a research report on Friday, April 23rd. Raymond James raised shares of Biogen from an underperform rating to a market perform rating in a research report on Monday. Morgan Stanley lowered their price target on shares of Biogen from $351.00 to $343.00 and set an overweight rating on the stock in a research report on Monday, April 19th. Cantor Fitzgerald reduced their price objective on shares of Biogen from $278.00 to $268.00 and set a neutral rating on the stock in a research note on Wednesday, February 17th. Finally, Bank of America upgraded shares of Biogen from an underperform rating to a neutral rating and increased their price objective for the stock from $235.00 to $400.00 in a research note on Monday. Sixteen equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $369.86.
YOU MAY ALSO LIKE
Businessmodernreaders.com

Vera Bradley (NASDAQ:VRA) Given Hold Rating at Robert W. Baird

VRA has been the subject of a number of other reports. Telsey Advisory Group lifted their price target on shares of Vera Bradley from $12.00 to $13.00 and gave the stock a “market perform” rating in a report on Thursday. Cowen reiterated a “market perform” rating and set a $12.00 price target on shares of Vera Bradley in a report on Monday, March 29th. TheStreet upgraded shares of Vera Bradley from a “c” rating to a “b-” rating in a report on Wednesday, March 3rd. Finally, Zacks Investment Research upgraded shares of Vera Bradley from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $13.25.
Stocksmodernreaders.com

Robert W. Baird Increases REV Group (NYSE:REVG) Price Target to $25.00

Other research analysts also recently issued reports about the company. BMO Capital Markets boosted their price objective on REV Group from $10.00 to $19.00 and gave the company a “market perform” rating in a research note on Friday, March 12th. Morgan Stanley boosted their price objective on REV Group from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday, April 16th. TheStreet raised REV Group from a “d+” rating to a “c-” rating in a research note on Thursday, March 4th. Finally, Zacks Investment Research raised REV Group from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Tuesday, March 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $17.17.
Stocksmodernreaders.com

Phreesia (NYSE:PHR) Price Target Raised to $62.00 at Robert W. Baird

PHR has been the topic of several other reports. Piper Sandler upped their price target on shares of Phreesia from $58.00 to $63.50 and gave the company an overweight rating in a research note on Monday. KeyCorp reduced their price objective on shares of Phreesia from $80.00 to $70.00 and set an overweight rating on the stock in a research note on Wednesday, March 31st. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Phreesia from a hold rating to a sell rating in a research note on Wednesday, April 14th. JPMorgan Chase & Co. assumed coverage on shares of Phreesia in a research note on Thursday, April 29th. They set an overweight rating on the stock. Finally, SVB Leerink reiterated a buy rating on shares of Phreesia in a research note on Sunday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $55.96.
Stocksmodernreaders.com

Broadcom (NASDAQ:AVGO) Given New $550.00 Price Target at Robert W. Baird

Other analysts also recently issued research reports about the stock. Mizuho upped their price target on shares of Broadcom from $490.00 to $520.00 and gave the stock a buy rating in a report on Friday. Oppenheimer restated a buy rating and set a $575.00 target price on shares of Broadcom in a research note on Thursday, May 27th. Cowen lifted their price target on Broadcom from $415.00 to $470.00 and gave the company a market perform rating in a research note on Tuesday, March 2nd. Rosenblatt Securities boosted their price target on Broadcom from $540.00 to $550.00 and gave the stock a buy rating in a report on Friday. Finally, Credit Suisse Group raised their price objective on Broadcom from $480.00 to $580.00 and gave the company an outperform rating in a research note on Tuesday, March 2nd. Five analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. Broadcom has an average rating of Buy and a consensus target price of $491.38.
Stocksmodernreaders.com

Asana’s (ASAN) “Buy” Rating Reaffirmed at Robert W. Baird

ASAN has been the subject of several other research reports. Royal Bank of Canada lifted their price target on Asana from $39.00 to $45.00 and gave the stock an outperform rating in a research report on Friday. JMP Securities lifted their price objective on Asana from $40.00 to $50.00 and gave the stock a market outperform rating in a report on Friday. They noted that the move was a valuation call. Jefferies Financial Group reduced their price objective on Asana from $40.00 to $35.00 and set a buy rating for the company in a report on Tuesday, May 18th. They noted that the move was a valuation call. Piper Sandler lifted their price objective on Asana from $45.00 to $52.00 and gave the stock an overweight rating in a report on Friday. Finally, Zacks Investment Research upgraded Asana from a sell rating to a hold rating in a report on Tuesday, May 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $37.77.
Stocksmodernreaders.com

Robert W. Baird Raises Fifth Third Bancorp (NASDAQ:FITB) Price Target to $44.00

A number of other analysts have also weighed in on FITB. JPMorgan Chase & Co. increased their target price on Fifth Third Bancorp from $38.50 to $42.00 and gave the stock a neutral rating in a research note on Monday, May 3rd. Jefferies Financial Group reiterated a buy rating and issued a $46.00 target price on shares of Fifth Third Bancorp in a research note on Friday, May 7th. Deutsche Bank Aktiengesellschaft increased their target price on Fifth Third Bancorp from $30.00 to $38.00 and gave the stock a hold rating in a research note on Thursday, April 1st. Zacks Investment Research lowered Fifth Third Bancorp from a buy rating to a hold rating and set a $44.00 price target on the stock. in a research note on Tuesday, May 11th. Finally, Wells Fargo & Company raised their price target on Fifth Third Bancorp from $28.00 to $36.00 and gave the company an equal weight rating in a research note on Thursday, April 1st. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Fifth Third Bancorp has a consensus rating of Buy and a consensus price target of $37.39.
Medical & Biotechmodernreaders.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Rating Reiterated by Robert W. Baird

Several other research analysts also recently weighed in on ORIC. Zacks Investment Research downgraded ORIC Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 5th. HC Wainwright boosted their price objective on ORIC Pharmaceuticals from $52.00 to $54.00 and gave the company a “buy” rating in a report on Thursday, March 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. ORIC Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $43.80.
Stocksmodernreaders.com

Robert W. Baird Initiates Coverage on R1 RCM (NASDAQ:RCM)

A number of other research analysts have also issued reports on the stock. KeyCorp boosted their price target on shares of R1 RCM from $27.00 to $35.00 in a research note on Tuesday, February 16th. TheStreet lowered shares of R1 RCM from a b- rating to a d rating in a research report on Friday, May 7th. SVB Leerink restated a buy rating on shares of R1 RCM in a research report on Thursday, May 27th. Zacks Investment Research lowered shares of R1 RCM from a hold rating to a sell rating in a research report on Tuesday, May 18th. Finally, Cowen upped their target price on shares of R1 RCM from $22.00 to $33.00 and gave the stock an outperform rating in a research report on Tuesday, February 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $28.83.
Medical & Biotechmodernreaders.com

Constellation Pharmaceuticals (NASDAQ:CNST) Stock Rating Lowered by Robert W. Baird

CNST has been the subject of several other reports. Zacks Investment Research lowered shares of Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 13th. Royal Bank of Canada restated a “buy” rating and set a $50.00 target price on shares of Constellation Pharmaceuticals in a research report on Wednesday, April 7th. Finally, JPMorgan Chase & Co. lowered shares of Constellation Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $37.75.
Marketsmodernreaders.com

Charles River Laboratories International (NYSE:CRL) Rating Reiterated by Robert W. Baird

CRL has been the subject of several other reports. KeyCorp upped their price target on Charles River Laboratories International from $340.00 to $360.00 and gave the stock an overweight rating in a research note on Friday, May 14th. JPMorgan Chase & Co. increased their target price on Charles River Laboratories International from $375.00 to $390.00 and gave the company an overweight rating in a research report on Friday, May 28th. Credit Suisse Group increased their target price on Charles River Laboratories International from $342.00 to $352.00 and gave the company a neutral rating in a research report on Friday, May 28th. Truist Securities increased their target price on Charles River Laboratories International from $324.00 to $369.00 and gave the company a buy rating in a research report on Tuesday, May 25th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Charles River Laboratories International from $334.00 to $354.00 and gave the company a buy rating in a research report on Wednesday, May 5th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $327.80.
Financial Reportsmodernreaders.com

McDonald’s (NYSE:MCD) Given “Buy” Rating at Robert W. Baird

A number of other analysts also recently issued reports on MCD. UBS Group lifted their price objective on shares of McDonald’s from $240.00 to $255.00 and gave the company a buy rating in a report on Thursday, April 22nd. Morgan Stanley boosted their target price on shares of McDonald’s from $250.00 to $259.00 and gave the stock an overweight rating in a report on Friday, April 30th. Argus boosted their target price on shares of McDonald’s from $245.00 to $260.00 and gave the stock a buy rating in a report on Friday, April 30th. Stifel Nicolaus boosted their target price on shares of McDonald’s from $225.00 to $240.00 and gave the stock a hold rating in a report on Monday, April 26th. Finally, JPMorgan Chase & Co. boosted their target price on shares of McDonald’s from $215.00 to $245.00 and gave the stock an overweight rating in a report on Monday, April 12th. They noted that the move was a valuation call. Eight research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. McDonald’s has an average rating of Buy and an average price target of $244.80.
Marketsmodernreaders.com

1Life Healthcare (NASDAQ:ONEM) Coverage Initiated by Analysts at Robert W. Baird

A number of other research analysts also recently issued reports on the stock. Zacks Investment Research raised shares of 1Life Healthcare from a sell rating to a hold rating in a research report on Thursday, February 25th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of 1Life Healthcare from $42.00 to $53.00 and gave the company a buy rating in a research report on Friday, February 26th. Truist reduced their price objective on shares of 1Life Healthcare from $56.00 to $48.00 and set a buy rating on the stock in a research report on Thursday, May 13th. KeyCorp assumed coverage on shares of 1Life Healthcare in a research report on Friday, May 21st. They set an overweight rating and a $41.00 price objective on the stock. Finally, Citigroup reduced their price objective on shares of 1Life Healthcare from $61.00 to $55.00 and set a buy rating on the stock in a research report on Thursday, May 13th. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. 1Life Healthcare presently has an average rating of Buy and an average price target of $48.29.
Stocksmodernreaders.com

GoodRx (NASDAQ:GDRX) Receives New Coverage from Analysts at Robert W. Baird

GDRX has been the topic of several other reports. Credit Suisse Group decreased their target price on shares of GoodRx from $50.00 to $45.00 and set an outperform rating on the stock in a research note on Tuesday, May 18th. SVB Leerink decreased their target price on shares of GoodRx from $61.00 to $56.00 and set an outperform rating on the stock in a research note on Friday, May 14th. Zacks Investment Research downgraded shares of GoodRx from a hold rating to a sell rating in a research note on Wednesday, May 26th. Citigroup lifted their target price on shares of GoodRx from $53.00 to $70.00 and gave the stock a buy rating in a research note on Friday, May 14th. Finally, Royal Bank of Canada reduced their price objective on shares of GoodRx from $56.00 to $50.00 and set an outperform rating on the stock in a research report on Friday, May 14th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. GoodRx currently has an average rating of Hold and an average target price of $49.71.